Olink to present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Olink Holding AB (Nasdaq: OLK) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 8:50 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olink Holding AB (Nasdaq: OLK) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 8:50 a.m. ET. CEO Jon Heimer and CFO Oskar Hjelm will engage in a virtual fireside chat during the event. A live and archived webcast will be accessible on the Olink investors' website for interested parties.
Founded in 2016 and based in Uppsala, Sweden, Olink focuses on advancing proteomics to enhance healthcare through innovative solutions utilized by biopharmaceutical firms and academic institutions.
Details
News Market Reaction – OLK
The recorded move for OLK in the trading session of this news was -1.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UPPSALA, Sweden, May 25, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that it will be participating in the Goldman Sachs 42nd Annual Global Healthcare Conference.
Jon Heimer, CEO and Oskar Hjelm, CFO are scheduled to participate in a virtual fireside chat on Wednesday, June 9th, 2021 at 8:50 a.m. ET.
A live and archived webcast will be available on the “Investors” section of the Olink website at investors.olink.com/investor-relations.
About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
Contacts
Media and Investor Relations
Olink Holding AB (publ), Stina Thorman, stina.thorman@olink.com, +46707187354
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.